Stratification by PSA level showed no significant differences between patients with PSA 3-4 ng/mL and those with PSA < 3 ng/mL (overall cancer detection: 83.3% vs. 63.6%, p = 0.67; clinically significant cancer: 50.0% vs. 31.8%, p = 0.73) (Tables 3-5; Figures 3, 4). Here, KLK3 is linked to cancer.